secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019052
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio Q3 net loss narrows to $10.1M; cash drops to $10.3M, raises $4.4M post-quarter
--------------------------------------------------------------------------------

- Cash and equivalents $10.3M at Sep 30, down from $16.1M at Jun 30 and $76.7M at Dec 31, 2022.
- Net loss of $10.1M ($1.23/share) vs $19.0M ($2.42) in Q3 2022; R&D expenses fell to $9.5M.
- CFIUS review of uBriGene asset sale restarted; new 45-day review period began Nov 14, lease transfer delayed.
- MB-106 CAR-T showed 95% ORR in follicular lymphoma (n=20) and two complete responses in WM patients.
- FDA accepted IND for MB-109 (MB-101 + MB-108) for recurrent glioblastoma; Phase 1 trial planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/0001558370-23-019052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023019052/tmb-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer